U.S. Biotech Stock News

NYSE:RDDT
NYSE:RDDTInteractive Media and Services

Reddit Turns Profitable As AI And Data Deals Shape Valuation Story

Reddit (NYSE:RDDT) has reported its first full year of GAAP profitability. Management attributes the profitable year to overseas expansion, AI driven advertising tools, and data licensing. New and expanded partnerships with Google Gemini and OpenAI ChatGPT are contributing to Reddit's data and AI related revenue streams. For investors watching NYSE:RDDT, the shift from meme stock status to a company reporting a full year of GAAP profitability marks a significant turning point. The shares...
NYSE:SEE
NYSE:SEEPackaging

Sealed Air (SEE) Net Margin Holds At 7.4% And Tests Bullish Profitability Narratives

Sealed Air (SEE) has put up a solid set of FY 2025 numbers so far, with Q3 revenue of US$1.4b and basic EPS of US$1.26, and trailing twelve month revenue of about US$5.3b paired with EPS of roughly US$2.70 as earnings from discontinued operations swing from small losses earlier in the year to a US$69.4m contribution in the latest quarter. Over recent periods the company has seen quarterly revenue move between US$1.27b and US$1.37b while quarterly EPS ranged from essentially flat at US$0.00 in...
NasdaqGS:MRVL
NasdaqGS:MRVLSemiconductor

Marvell Expands AI Data Center Role With Celestial AI And PCIe 8.0

Marvell Technology completed its acquisition of Celestial AI, adding optical interconnect capabilities for large AI workloads. The company showed a working PCIe 8.0 SerDes technology demo at DesignCon 2026 for next generation AI and data center systems. These moves align with Marvell's focus on high bandwidth infrastructure for cloud and AI data centers. Marvell Technology (NasdaqGS:MRVL) is leaning further into AI and cloud infrastructure with the Celestial AI acquisition and its early...
NYSE:TGNA
NYSE:TGNAMedia

Tegna (TGNA) Earnings Slide And Margin Compression Reinforce Bearish Profitability Narratives

Tegna (TGNA) has laid out its FY 2025 scorecard so far with Q3 revenue of US$650.8 million and basic EPS of US$0.23, alongside trailing twelve month revenue of about US$2.9 billion and EPS of US$2.13 that sit against a net profit margin of 11.9%. The company has seen quarterly revenue move from US$710.4 million in Q2 2024 to US$675.0 million in Q2 2025, with EPS shifting from US$0.48 to US$0.42 over the same period, as trailing earnings also reflect a one off US$139.1 million gain that shapes...
NYSE:SEMR
NYSE:SEMRSoftware

A Look At Semrush Holdings (SEMR) Valuation As Long Term Returns Outpace Recent Share Performance

Semrush Holdings (SEMR) continues to draw interest from investors focused on digital marketing tools, with recent attention centered on how its current share price and fundamentals line up after a mixed pattern of near term and longer term returns. See our latest analysis for Semrush Holdings. At a share price of $11.80, Semrush’s short term share price returns have been slightly negative, while its 1 year and 3 year total shareholder returns of 5.9% and 44.1% point to a stronger longer term...
NYSE:VG
NYSE:VGOil and Gas

Venture Global (VG) Net Margin At 19% Challenges Bearish Profitability Narratives

Venture Global FY 2025 Earnings Snapshot Venture Global (VG) has put fresh numbers on the board for FY 2025, with third quarter revenue of about US$3.3b and basic EPS of US$0.18, setting the tone for how the rest of the year will be judged. The company has seen revenue move from US$926m in Q3 2024 to US$3.3b in Q3 2025. Basic EPS shifted from a loss of US$0.15 in Q3 2024 to a profit of US$0.18, and trailing twelve month EPS reached US$0.86 on revenue of about US$10.8b. With trailing net...
NYSE:MTG
NYSE:MTGDiversified Financial

Is MGIC Investment (MTG) Quietly Rewriting Its Edge Through Market Share Gains And Tech Spending?

MGIC Investment Corporation’s recently filed 2025 Form 10-K shows past-year growth in insurance in force and market share, supported by reinsurance and capital management actions. The filing also highlights how technology and innovation spending is being used alongside disciplined pricing and risk controls to sustain MGIC’s competitive position despite pressure on premium volumes. We’ll now examine how MGIC’s market share gains and technology investment may reshape its existing investment...
NYSE:PWR
NYSE:PWRConstruction

Is It Too Late To Consider Quanta Services (PWR) After A 128% One-Year Surge?

If you are wondering whether Quanta Services is still reasonably priced after a strong run, you are not alone. This article is built to help you frame what that current share price might mean for long term investors. The stock recently closed at US$572.66, with returns of 4.3% over 7 days, 20.7% over 30 days, 30.2% year to date and 128.5% over the past year, while the 3 year gain is 252% and the 5 year gain is very large. Recent attention around Quanta Services has centered on its role as a...
NasdaqGS:SBLK
NasdaqGS:SBLKShipping

Star Bulk Carriers (SBLK) Is Up 6.5% After Boosting Dividend And Approving New Buyback Plan

In late February 2026, Star Bulk Carriers Corp. reported fourth-quarter 2025 results showing revenue of US$300.59 million, net income of US$65.15 million, earnings per share of US$0.57, and declared a quarterly cash dividend of US$0.37 per share payable in March 2026. The company also completed a prior repurchase plan and authorized a new US$100 million share buyback, signaling an ongoing focus on returning cash to shareholders while investing in fleet efficiency and environmental...
NasdaqGS:EFSC
NasdaqGS:EFSCBanks

Will EFSC’s Branch Expansion, Capital Returns and Debt Moves Reshape Enterprise Financial Services’ Core Narrative?

Enterprise Financial Services Corp recently filed its 2025 Form 10-K, outlining its past-year performance, the acquisition of 12 First Interstate Bank branches in Arizona and Kansas City, higher quarterly dividends, share repurchases, and balance sheet actions including subordinated debt redemption and a lower-cost senior note issuance. An interesting insight from the filing is how the combination of branch purchases, capital returns, and debt refinancing reflects management’s emphasis on...
NYSE:NWN
NYSE:NWNGas Utilities

The Bull Case For Northwest Natural Holding (NWN) Could Change Following Strong 2025 Results And MX3 Expansion Project

In late February 2026, Northwest Natural Holding reported higher fourth-quarter and full-year 2025 results, with Q4 net income rising to US$57.79 million on sales of US$394.16 million and full-year net income reaching US$113.32 million on sales of US$1.29 billion, while initiating 2026 EPS guidance of US$2.95–US$3.15 and filing a US$57.81 million ESOP-related common stock shelf registration. Management also unveiled the long-term MX3 gas storage expansion project and reaffirmed 2026–2030 EPS...
NYSE:HL
NYSE:HLMetals and Mining

Hecla Mining (HL) Valuation Check After Greens Creek Tailings Progress And Strong 2025 Earnings Update

Hecla Mining (HL) is back in focus after fresh news from its Greens Creek mine tailings project and recently released 2025 earnings, along with new 2026 production guidance and board level changes. See our latest analysis for Hecla Mining. The recent Greens Creek tailings progress, strong 2025 earnings update and fresh 2026 production guidance have coincided with a 9.37% 1 month share price return and a 385.91% 1 year total shareholder return. This suggests momentum has been building despite...
NYSE:TPB
NYSE:TPBTobacco

Turning Point Brands (TPB) Margin Compression Tests Bullish Growth Narrative After Q3 Earnings

Turning Point Brands (TPB) has reported third quarter FY 2025 revenue of US$119 million and basic EPS of US$1.16, with trailing twelve month revenue at US$436 million and basic EPS of US$3.31. The company has seen quarterly revenue move from US$90.7 million in the third quarter of 2024 to US$119 million in the third quarter of 2025, while quarterly basic EPS went from US$0.71 to US$1.16 over the same span. This sets up a story where higher recent earnings meet a shift in net profit margins...
NYSE:SMR
NYSE:SMRElectrical

Assessing NuScale Power (SMR) Valuation After Recent Share Price Weakness

NuScale Power (SMR) has drawn investor attention after recent trading left the stock with a return of about 3.6% over the past week, while showing double digit declines over the month and the past 3 months. See our latest analysis for NuScale Power. Zooming out, NuScale Power’s recent 3.6% 7 day share price return sits against a 1 month share price decline of about 25% and a year to date share price fall of roughly 20%. Its 3 year total shareholder return is about 28%, which hints that recent...
NasdaqGS:NTNX
NasdaqGS:NTNXSoftware

Nutanix (NTNX) Is Up 7.8% After AMD’s US$250M Agentic AI Partnership Commitment – What’s Changed

In February 2026, AMD and Nutanix announced a multi-year partnership to build an open, full-stack AI infrastructure platform for agentic AI, alongside AMD’s planned US$150,000,000 equity investment in Nutanix at US$36.26 per share and up to US$100,000,000 in joint engineering and go-to-market funding. The deal effectively ties Nutanix’s hybrid cloud software to AMD’s EPYC CPUs, Instinct GPUs, and ROCm ecosystem, positioning the two companies to offer enterprises an alternative to vertically...
NasdaqGS:KC
NasdaqGS:KCIT

Evaluating Kingsoft Cloud Holdings (NasdaqGS:KC) After Higher Related Party Lease Caps Raise Fixed Cost Concerns

Kingsoft Cloud Holdings (NasdaqGS:KC) recently raised the annual caps on related-party property services and lease transactions with Kingsoft Corporation for 2026 and 2027, prompting a roughly 6% share price drop as investors assessed higher fixed cost exposure. See our latest analysis for Kingsoft Cloud Holdings. The latest announcement comes after a period of mixed performance, with a 17.3% year to date share price return but a 14.3% decline in 1 year total shareholder return, while the 3...
NasdaqCM:CGEN
NasdaqCM:CGENBiotechs

Compugen (CGEN) Quarterly Loss Near US$7 Million Tests Bullish Profitability Narrative

Compugen (CGEN) has just reported its FY 2025 results, with Q3 revenue of US$1.9 million and a basic EPS loss of US$0.07. Trailing twelve month figures show revenue of US$6.9 million and a basic EPS loss of US$0.30. The company has seen quarterly revenue range from US$1.3 million to US$2.3 million in FY 2025 so far, with basic EPS losses between US$0.07 and US$0.08 over the same stretch. This sets up a picture in which top line consistency still sits alongside negative earnings. With revenue...
NYSE:O
NYSE:ORetail REITs

Is It Time To Reassess Realty Income (O) After Its Strong 1 Year Share Price Run?

If you are wondering whether Realty Income is fairly priced at its current level, this article explains how its market value compares with several valuation checks. With the share price at US$67.56 and returns of 1.3% over 7 days, 10.5% over 30 days, 17.9% year to date, 24.1% over 1 year, 24.1% over 3 years and 48.6% over 5 years, many investors are reassessing what they are willing to pay for the stock. Recent attention on Realty Income has centered on its role as a large US REIT for...
NYSE:EPD
NYSE:EPDOil and Gas

A Look At Enterprise Products Partners (EPD) Valuation After Its Earnings Beat And Growth Outlook Update

Enterprise Products Partners (EPD) is back in focus after quarterly results that exceeded revenue and EBITDA expectations. The company also announced new infrastructure projects and received positive analyst commentary tied to its long distribution track record and disciplined balance sheet. See our latest analysis for Enterprise Products Partners. The latest quarterly beat and a full pipeline of growth projects have coincided with a solid 11.15% 1 month share price return and a 15.32% 3...
NasdaqGS:AGIO
NasdaqGS:AGIOBiotechs

A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND UAE Thalassemia Approval

Why PYRUKYND’s UAE approval is drawing fresh attention to Agios Pharmaceuticals The recent approval of PYRUKYND (mitapivat) in the United Arab Emirates for certain thalassemia patients gives Agios Pharmaceuticals (AGIO) a new commercial foothold in the Gulf region and a fresh catalyst for investor interest. See our latest analysis for Agios Pharmaceuticals. Investors have been reacting to a mix of clinical milestones and events such as Agios’ upcoming presentation at the TD Cowen Health Care...
NasdaqGS:RRR
NasdaqGS:RRRHospitality

A Look At Red Rock Resorts (RRR) Valuation After Recent Share Price Weakness

Red Rock Resorts (RRR) has drawn attention after recent share performance, with a 1 day return of negative 3.15% and mixed moves over the past week, month and past 3 months. See our latest analysis for Red Rock Resorts. That 1 day share price decline and softer 30 day share price return sit alongside a 2.26% 3 month share price gain and a much stronger 1 year total shareholder return of 30.46%. This suggests that longer term momentum has been more positive than the very recent trading...
NYSE:NOC
NYSE:NOCAerospace & Defense

Assessing Whether Northrop Grumman (NOC) Is Fairly Valued After Strong Multi Year Shareholder Returns

Why Northrop Grumman stock is on investors’ radar Northrop Grumman (NOC) has drawn attention recently as investors weigh its current valuation against its track record of revenue and net income growth, along with strong multi year total returns. See our latest analysis for Northrop Grumman. At a share price of US$724.38, Northrop Grumman has recently seen a 1 day share price return of 1.9% and a 30 day share price return of 4.6%. Its 1 year total shareholder return of 55.5% and 5 year total...
NYSE:HNGE
NYSE:HNGEHealthcare

Assessing Hinge Health’s Valuation After A Recent Share Price Rebound

What Hinge Health’s latest trading move signals for investors Hinge Health (HNGE) has caught investor attention after a recent move in its share price, with the stock closing at US$42.76 as short term returns and fundamentals offer a mixed picture. See our latest analysis for Hinge Health. The recent 7 day share price return of 11.21% and 30 day share price return of 22.52% sit against a weaker 90 day share price return of 8.16% and year to date share price return of 6.15%. This suggests...
NasdaqGS:ASND
NasdaqGS:ASNDBiotechs

Assessing Ascendis Pharma (ASND) Valuation After FDA Accelerated Approval For YUVIWEL

Ascendis Pharma (NasdaqGS:ASND) is in focus after the U.S. FDA granted accelerated approval for YUVIWEL, a once weekly treatment for children with achondroplasia, along with a Rare Pediatric Disease Priority Review Voucher. See our latest analysis for Ascendis Pharma. The FDA approval, Rare Pediatric Disease Priority Review Voucher and upcoming conference appearance at the TD Cowen Health Care Conference come alongside a 1 year total shareholder return of 59.34% and a 3 month share price...